Company intelligence / Profile preview
Garonit Pharmaceutical
Hangzhou, Zhejiang, Chinagaronitpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Garonit Pharmaceutical is a clinical-stage biotechnology company focused on the development of innovative small molecule therapeutics for metabolic diseases, particularly Type 2 diabetes. The company's lead research efforts center on G protein-coupled receptor 119 (GPR119) agonists, which aim to enhance insulin secretion and improve glucose homeostasis. Garonit is also exploring combination therapies involving SGLT2 inhibitors and DPP-4 inhibitors to provide comprehensive management for diabetic patients. Based in China, the company leverages its internal R&D capabilities to advance its pipeline through early-stage clinical trials.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Garonit Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Garonit Pharmaceutical.